VRTX - Vertex Pharmaceuticals Incorporated
| Previous close | 191.06 |
| Open | 190.37 |
| Bid | 190.93 x 1800 |
| Ask | 191.07 x 1000 |
| Day's range | 186.52 - 192.54 |
| 52-week range | 151.80 - 195.81 |
| Volume | 1,090,813 |
| Avg. volume | 1,218,490 |
| Market cap | 49.173B |
| Beta (3Y monthly) | 1.03 |
| PE ratio (TTM) | 22.45 |
| EPS (TTM) | 8.52 |
| Earnings date | 30 Oct 2019 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 222.90 |
- Zacks
Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth
Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Business Wire
ADDING MULTIMEDIA FDA Approves TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older Who Have at Least One F508del Mutation
Vertex Pharmaceuticals Incorporated (VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved TRIKAFTA™ (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of cystic fibrosis (CF) in people ages 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, the most common CF-causing mutation. With this approval, for the first time, approximately 6,000 people with CF ages 12 years and older who have one F508del mutation and one minimal function mutation (F/MF) have a medicine that targets the underlying cause of their CF.
- Zacks
Biotech Stock Roundup: BIIB Up on AD Data, ALXN to Buy ACHN & Other Pipeline Updates
Key highlights of the past week include acquisition news, and regulatory and pipeline updates.
- Zacks
The Zacks Analyst Blog Highlights: Chipotle Mexican Grill, Vertex Pharmaceuticals, American Electric Power Company, Verizon Communications and V.F.
The Zacks Analyst Blog Highlights: Chipotle Mexican Grill, Vertex Pharmaceuticals, American Electric Power Company, Verizon Communications and V.F.
- Zacks
What's in Store for IDEXX Laboratories' (IDXX) Q3 Earnings?
Growth in Rapid Assays and Veterinary Software revenues is expected to get reflected in IDEXX's (IDXX) third-quarter results.
- Business Wire
Vertex to Announce Third-Quarter 2019 Financial Results on October 30
Vertex Pharmaceuticals Incorporated (VRTX) will report its third quarter 2019 financial results on Wednesday, October 30, 2019 after the financial markets close. An archived webcast will be available on the company's website. Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases.
- Business Wire
FDA Approves TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older Who Have at Least One F508del Mutation
Vertex Pharmaceuticals Incorporated (VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved TRIKAFTA™ (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of cystic fibrosis (CF) in people ages 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, the most common CF-causing mutation. With this approval, for the first time, approximately 6,000 people with CF ages 12 years and older who have one F508del mutation and one minimal function mutation (F/MF) have a medicine that targets the underlying cause of their CF.
- Business Wire
Spanish Government Approves National Reimbursement of ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor) in Combination With KALYDECO® (ivacaftor)
Vertex Pharmaceuticals Incorporated (VRTX) today announced that the Spanish Government has approved terms for the national reimbursement of ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor) in combination with KALYDECO® (ivacaftor) for eligible patients in Spain living with cystic fibrosis (CF). Under the terms announced today, children ages 6 to 11 years with CF who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene can be treated with ORKAMBI. Patients ages 12 years and older who either have two copies of the F508del mutation, or one copy of the F508del mutation and a copy of one of the other 14 mutations approved within the license in which the CFTR protein shows residual activity, can be treated with SYMKEVI in combination with KALYDECO.
- Zacks
Is Walgreens Boots (WBA) Likely to Disappoint in Q4 Earnings?
Persistent de-emphasizing of tobacco is hurting growth, which should get reflected in the upcoming quarterly results of Walgreens Boots Alliance (WBA).
- Zacks
Alexion Gets FDA Approval for Label Expansion of Ultomiris
Alexion (ALXN) obtains FDA approval for the label expansion of Ultomiris for the treatment of ultra-rare disease, aHUS.
- Zacks
5 Large-Cap Stocks Set to Beat Earnings Estimates This Month
Third-quarter 2019 earnings results so far are not as disappointing as expected initially. However, the forecast of overall earnings dip in the third quarter is still looming large.
- Business Wire
Vertex Announces Reimbursement of Cystic Fibrosis Medicines SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Patients Ages 12 and Older, and ORKAMBI® (lumacaftor/ivacaftor) in Children Ages 2 to 5, With Certain CFTR Mutations in Australia
Vertex Pharmaceuticals Incorporated (VRTX) today announced that SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) is reimbursed in Australia for people with cystic fibrosis (CF) ages 12 years and older who are homozygous for the F508del mutation or who have one copy of the F508del mutation and another responsive residual function (RF) mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. People with CF who have one copy of the F508del mutation and another responsive RF mutation in the CFTR gene will have access to a medicine for the cause of their CF for the first time.
- Zacks
What's in Store for Align Technology's (ALGN) Q3 Earnings?
We are optimistic that Align Technology's (ALGN) Invisalign product portfolio has shown continued strength in the third quarter.
- Business Wire
Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Eligible Infants with Cystic Fibrosis as Early as 6 Months of Age
Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for KALYDECO® (ivacaftor), to include use in infants with cystic fibrosis (CF) ages 6 months to less than 12 months who have one of the following mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. If the European Commission issues a favorable adoption of the EMA CHMP opinion for the extension of indication, ivacaftor will be the first and only medicine approved in Europe to treat the underlying cause of CF in patients ages 6 months to less than 12 months, who have specific mutations in the CFTR gene.
- Zacks
Will New Alliances Aid Quest Diagnostics (DGX) Q3 Earnings?
Quest Diagnostics (DGX) is likely to have retained its two-pronged agenda to accelerate growth and drive operational excellence in the third quarter.
- Zacks
The Zacks Analyst Blog Highlights: Southern Company, Applied Materials, Vertex Pharmaceuticals, NVIDIA and Edwards Lifesciences
The Zacks Analyst Blog Highlights: Southern Company, Applied Materials, Vertex Pharmaceuticals, NVIDIA and Edwards Lifesciences
- Zacks
What's in Store for Edwards Lifesciences' (EW) Q3 Earnings?
The recent full-market launch of the HemoSphere platform with the FloTrac System and Acumen Hypotension Predictive Index should reflect in Edwards Lifesciences' (EW) third-quarter results.
- Zacks
Top Research Reports for Southern, Applied Materials & Vertex
Top Research Reports for Southern, Applied Materials & Vertex
- Zacks
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?
Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
CRISPR Therapeutics Enters New License Agreement, Shares Up
CRISPR Therapeutics (CRSP) looks to strengthen its CAR-T therapy programs through its agreement with KSQ Therapeutics.
- Zacks
Can Structural Heart Strength Aid Abbott (ABT) Q3 Earnings?
Abbott (ABT) has been growing popular with developments in its flagship, market leading device for the treatment of mitral regurgitation, MitraClip.
- Zacks
Can Balanced Segmental Growth Aid Abbott (ABT) Q3 Earnings?
Abbott (ABT) is steadily gaining prominence for developments in its flagship, sensor-based continuous glucose monitoring (CGM) system of FreeStyle Libre.
- Zacks
Can Vertex (VRTX) Keep the Earnings Surprise Streak Alive?
Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- Zacks
Is Vertex Pharmaceuticals (VRTX) Outperforming Other Medical Stocks This Year?
Is (VRTX) Outperforming Other Medical Stocks This Year?
- Simply Wall St.
A Look At The Fair Value Of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Vertex...
